Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILs in Advanced Gynecological and Breast Cancer
NCT05152797Phase 2Not yet recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Adoptive Cell Transfer
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes in Cervical Cancer (CC), ovarian cancer, endometrial cancer (EC), breast cancer, sponsored by Women's Hospital, Zhejiang University School of Medicine. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
Cervical Cancer (CC)ovarian cancerendometrial cancer (EC)breast cancer
Beyond the preview
Go deeper on NCT05152797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152797.